Advertisement

Management of Recurrent or Residual Cervical Cancer with Cisplatin and Topotecan Combination Therapy in a Palliative Setting: A Prospective Study

  • Todak Taba
  • Debabrata Barmon
  • Dimpy Begum
  • A. C. Kataki
  • Helen Kamei
Original Article
  • 6 Downloads

Abstract

Context

Treatment options for patients with recurrent or residual cervical tumour are limited. Several new cytotoxic drugs have been recently investigated, comparing single agent with multiple drugs combination. The uses of chemotherapy in these cases are considered palliative because of low response rates and a negligible impact on long-term survival.

Aims and Objectives

To evaluate the efficacy and side effects of cisplatin plus topotecan combined chemotherapy in persistent or recurrent cervical cancer not amenable to curative treatment by surgery and/or radiation and to evaluate the median progression-free interval and overall survival after the completion of treatment.

Materials and Methods

In total, 17 patients with residual or recurrent cervical cancer were enrolled in this trial. They were given a standard dose of chemotherapy according to their body surface area, i.e. topotecan 0.75 mg/m2 intravenously on day 1, 2 and 3, and cisplatin 50 mg/m2 intravenously on day 1. Treatments were repeated every 21 days for 6 cycles or until disease progression or unacceptable toxicities and then followed up 3 months for 1 year. OS and PFS rates were estimated by means of the Kaplan–Meier method. Toxicities analysis was also done.

Results

Topotecan and cisplatin combined chemotherapy was well tolerated by all the patients with grade 2 neutropenia, leukopenia and thrombocytopenia occurring in 5.8%, anaemia in 53% and mild nausea in 11.8%. There were complete remission in 2 patients (11.8%) and partial remission in another 3 patients (17.6%) at the end of study with overall response of 29.4%. There were 3 patients (17.6%) with stable disease. The median OS was 10 months, and the median PFS was 4 months.

Conclusion

Topotecan and cisplatin combination was found to be effective, safe and well tolerated in patients with persistent or recurrent cervical cancer.

Keywords

Topotecan Cisplatin Residual or recurrent cervical cancer Palliative chemotherapy 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    GLOBOCAN 2012 (IARC), Section of cancer surveillance.Google Scholar
  2. 2.
    Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Forman D, de Martel C, Lacey CJ, et al. Global burden of human papilloma virus and related diseases. Vaccine. 2012;30(suppl 5):F12–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Globocan 2008. Cancer Incidence and Mortality Worldwide. https://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php.
  5. 5.
    Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45:127–8.CrossRefGoogle Scholar
  6. 6.
    Alfen GC, Kristensen GB, Skovlund E, et al. Histological subtypes has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix; a population based study of prognostic factors in 505 patients with non-squamous cell carcinomas of cervix. Cancer. 2001;92:2471–83.CrossRefGoogle Scholar
  7. 7.
    Kaarthigeyan K. Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Onol. 2012;33(1):7–12.CrossRefGoogle Scholar
  8. 8.
    Howlander N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, YU M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD; 2017. https://seer.cancer.gov/csr/1975_2014/.
  9. 9.
    Barmon D, Sharma JD, Barmon D, Kataki AC. Epidemiology of Gynaecological cancer in Kamrup urban district. Indian J Cancer. 2017;54(1):388–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Recurrent cervical cancer. Cancer Treatment Centres of America.Google Scholar
  11. 11.
    Delgado G, Bundu B, Ziano R, et al. Prospective surgical-pathological study of disease free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecoloncol. 1990;38:352–7.Google Scholar
  12. 12.
    Ziano RJ, Ward S, Delgado E, et al. Histopathological predictors of the behaviour of.surgically treated stage IB squamous cell carcinoma of the cervix. A gynecologic oncology group study. Cancer. 1992;69:1750–8.CrossRefGoogle Scholar
  13. 13.
    Burgghardt E, Baltzer J, Tulusan AH, et al. Results of surgical treatment of 1028 cervical cancers studied with volumetry. Cancer. 1992;70:648–55.CrossRefGoogle Scholar
  14. 14.
    Stehman FB, Bundy BN, Disaia PJ, et al. Carcinoma of the cervix treated with radiation therapy. I. A multivariate analysis of prognostic variables in the gynecologic oncology group. Cancer. 1991;67:2776–85.CrossRefPubMedGoogle Scholar
  15. 15.
    Perez CA, Grigsby PW, Camel HM, et al. Irradiation alone or combined with surgery in stage IB, IIA and IIB carcinoma of the uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys. 1995;31:703–16.CrossRefPubMedGoogle Scholar
  16. 16.
  17. 17.
    Van Nagell JR Jr, Rayburn W, Donalson ES, et al. Therapeutic implications of patterns of recurrence in cancer of the uterine cervix. Cancer. 1979;44:2354–61.CrossRefPubMedGoogle Scholar
  18. 18.
    Eifel PJ, Jhingran A, Brown J, et al. Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer. 2006;16:1006–111.CrossRefGoogle Scholar
  19. 19.
    Leitao MM, Chi DS. Recurrent cervical cancer. Curr Treat Options Oncol. 2002;3:105–11 (view article: Google Scholar).CrossRefPubMedGoogle Scholar
  20. 20.
    Thigpen T, Shingleton H, Homesley H, et al. Cisplatin in the treatment of advanced or recurrent squamous cell carcinoma of cervix: a phase II study of the gynecologic oncology group. Cancer. 1981;48:899–903 (view article: Google Scholar: PubMed/NCBI).CrossRefPubMedGoogle Scholar
  21. 21.
    Molpus KL, Redlin-Frazier S, Reed G, et al. Postoperative pelvic irradiation in early stage uterine mixed mulleriantumors. Eur J Gynecol Oncol. 1998;19:541–6.Google Scholar
  22. 22.
    Vermorken JB. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review. Int J Gynecol Cancer. 1993;3:129–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Hogg R, Friedlander M. Role of systemic chemotherapy in metastatic cervical cancer. Expert Rev Anticancer Ther. 2003;3:234–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Long HJ III. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007;25:2966–74.CrossRefPubMedGoogle Scholar
  25. 25.
    Bonomi P, Blessing JA, Stehman FB, et al. Randomised trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix; a gynecologic oncology group study. J Clin Oncol. 1985;3:1079–85.CrossRefPubMedGoogle Scholar
  26. 26.
    Leath CA III, Straughn JM Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol. 2013;129:251–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Hirte HW, Strychowsky JE, Oliver T, et al. Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Int J Gynecol Cancer. 2007;17:1194–204.CrossRefPubMedGoogle Scholar
  28. 28.
    Cadron I, Van Gorp T, Amant F, et al. Chemotherapy for recurrent cervical cancer. Gynecol Oncol. 2007;107(1 suppl 1):S113–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008;110:S67–71.CrossRefPubMedGoogle Scholar
  30. 30.
    Movva S, Rodriguez L, Arias-Pulido H, et al. Novel chemotherapy approaches for cervical cancer. Cancer. 2009;115:3166–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Mountzios G, Soultati A, Pectasides D, et al. Developments in the systemic treatment of metastatic cervical cancer. Cancer Treat Rev. 2013;39:430–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomised phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncologic Group study. J Clin Oncol. 2005;23(21):4626–33 Epub 2005 May 23.CrossRefPubMedGoogle Scholar
  33. 33.
    Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol. 2009;27:4649–55.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–43.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kitagawa R, Katsumata K, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial (JCOG0505). J Clin Oncol. 2015;33:2129–35.CrossRefPubMedGoogle Scholar
  37. 37.
    Shamida M, Sato S, Oishi T, et al. Feasibility study on combination chemotherapy using topotecan and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer. Int J Clin Oncol. 2016;21(5):969–74 Epub 2016 May 3.CrossRefGoogle Scholar
  38. 38.
    Fiorica J, Holloway R, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and non squamous carcinoma of the cervix. Gynecol Oncol. 2002;85(1):89–94.CrossRefPubMedGoogle Scholar
  39. 39.
    Lee YY, Lee JW, Park HS, et al. Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. Gynecol Oncol. 2010;119(1):87–91.  https://doi.org/10.1016/j.ygyno.2010.05.030 Epub 2010 Jun 26.CrossRefPubMedGoogle Scholar
  40. 40.
    Moon JY, et al. The combination of cisplain and topotecan as a second line treatment for patients with advanced/recurrent uterine cervix cancer. Medicine (Bartimore). 2018;97(14):e0340.  https://doi.org/10.1097/MD.0000000000010340.CrossRefGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2018

Authors and Affiliations

  • Todak Taba
    • 1
  • Debabrata Barmon
    • 1
  • Dimpy Begum
    • 1
    • 3
  • A. C. Kataki
    • 2
  • Helen Kamei
    • 1
  1. 1.Department of Gynaecologic OncologyDr. B. Borooah Cancer InstituteGuwahatiIndia
  2. 2.Dr. B. Borooah Cancer InstituteGuwahatiIndia
  3. 3.GuwahatiIndia

Personalised recommendations